Is Myriad Genetics, Inc. overvalued or undervalued?

As of 4 November 2019, the valuation grade for Myriad Genetics, Inc. has moved from very expensive to risky. The company is currently assessed as undervalued given its significant price-to-book value of 0.67 and an EV to sales ratio of 0.54, indicating that the market may not be fully recognizing the potential value of its assets. However, the negative P/E ratio reflects ongoing losses, which complicates the valuation picture.
In comparison to peers, Myriad Genetics shows a stark contrast with TransMedics Group, Inc., which has a P/E ratio of 94.14, and Veracyte, Inc., with a P/E of 54.69, both categorized as fairly valued. Notably, Myriad's ROCE stands at -13.04% and ROE at -9.36%, suggesting operational challenges that may be influencing its market perception. The company's stock has underperformed significantly against the S&P 500 over multiple time frames, particularly with a year-to-date decline of 64.55%, reinforcing the narrative of undervaluation amidst operational difficulties.